Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prevalence and complementary distribution of FGFR3 alterations and ERBB2 amplification in metastatic urothelial carcinoma: a nationwide registry analysis.

International journal of clinical oncology - 1 Sept 2026

Hara Takuto, Tobe Taisuke, Ueki Hideto, Wakita Naoto, Okamura Yasuyoshi, Bando Yukari, Suzuki Kotaro, Terakawa Tomoaki, Hyodo Yoji, Yao Akihisa, Chiba Koji, Teishima Jun, Miyake Hideaki

Abstract excerpt

BACKGROUND: Fibroblast growth factor receptor 3 (FGFR3) alterations and ERBB2 (HER2) amplification are clinically actionable genomic events in metastatic urothelial carcinoma (mUC). However, their prevalence and overlap in metastatic-specific cohorts remain incompletely defined. We evaluated their nationwide distribution and co-occurrence using the Japanese C-CAT registry. METHODS: This retrospective study...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Transitional Cell
Share to Erb-b2 Receptor Tyrosine Kinases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Amplification

Share to Neoplasm Metastasis

Share to Receptor, Fibroblast Growth Factor, Type 3

Share to Registries

Share to Urinary Bladder Neoplasms

Source

Identifiers

PMID: 42365196
DOI: 10.1007/s10147-026-03117-9

Genes

FGFR3
ERBB2
CAT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prevalence and complementary distribution of FGFR3 alterations and ERBB2 amplification in metastatic urothelial carcinoma: a nationwide registry analysis.PMID 42365196Read ↗

FGFR3 Mutations in Urothelial Carcinoma: A Single-Center Study Using Next-Generation SequencingSemantic proximity Read ↗

Role of FGFR3 in bladder cancer: Treatment landscape and future challenges.Semantic proximity Read ↗

Reflex somatic testing for the detection of FGFR alterations in urinary tract carcinomas: A dual-institutional experience.Semantic proximity Read ↗

FGFR1/3 Signaling as an Achilles' Heel of Phenotypic Diversity in Urothelial Carcinoma.Semantic proximity Read ↗

Nested and Large Nested Subtypes of Urothelial Carcinoma of the Upper Urinary Tract: A Multi-institutional Study.Semantic proximity Read ↗

Insights of fibroblast growth factor receptor 3 aberrations in pan-cancer and their roles in potential clinical treatment.Semantic proximity Read ↗

Molecular profile of micropapillary urothelial carcinoma of the urinary bladder: An analysis of 99 cases by next-generation sequencing.Semantic proximity Read ↗

Comprehensive Genomic Characterization of Upper Tract Urothelial Carcinoma.Semantic proximity Read ↗

Fibroblast Growth Factor Receptor 3 Alteration Status is Associated with Differential Sensitivity to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial Carcinoma.Semantic proximity Read ↗

Current Knowledge on Genomic Profiling of Upper Tract Urothelial CarcinomaSemantic proximity Read ↗

Prognostic markers in invasive bladder cancer: FGFR3 mutation status versus P53 and KI-67 expression: a multi-center, multi-laboratory analysis in 1058 radical cystectomy patients.Semantic proximity Read ↗

The Impact of Fibroblast Growth Factor Receptor Alterations in Clinical Outcomes of Patients With Advanced Urothelial Carcinoma: Real-World Data From a Latin American Population.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.